You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 20, 2025

CLINICAL TRIALS PROFILE FOR COAGULATION FACTOR XIII A-SUBUNIT (RECOMBINANT)


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for coagulation factor xiii a-subunit (recombinant)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00377143 ↗ PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care Withdrawn University of Florida Phase 4 2006-07-01 Warfarin (also called Coumadin®) is an anticoagulant drug (blood thinner) given to patients to help prevent blood clots from forming or to help prevent the growth of an existing blood clot. The purpose of this study is to collect information on a possible method used to determine the best warfarin dose for people before they start warfarin. This study will focus on finding out if a person's stable dose can be better predicted by using a new approach (called "pharmacogenetic-guided dosing") compared to the current warfarin dosing method. The pharmacogenetic-guided dosing method (the new warfarin dosing method) will use a person's specific health and genetic information to calculate a patient's warfarin dose at the beginning of warfarin treatment. The hope is that through this research, we may someday be able to use an individual's genetic information to guide the selection of their specific warfarin dose at the beginning of treatment, leading to precise warfarin dosing and less need for the current trial and error process.
NCT06186648 ↗ Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome Recruiting Hoffmann-La Roche Phase 2 2024-03-21 This is a national clinical trial, multicentric (28 centers), non-randomized phase 2 study. Population: Patients with previously untreated Richter's syndrome (RS), defined as the occurrence of an aggressive lymphoma (of diffuse large B-cell lymphoma histology) in a patient with chronic lymphocytic leukemia (CLL). Study treatment: The duration of each cycle is 21 days. Cycle 1: Participants will receive standard of care doses of R-CHOP in cycle 1 as follows: - Rituximab 375 mg/m² IV Day 1 - Cyclophosphamide 750 mg/m² IV Day 1 - Doxorubicin 50 mg/m² IV Day 1 - Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1 - Prednisone 60 mg/m2 per day PO Day 1-5 Cycle 2: In order to minimize cytokine release syndrome (CRS), participants will then receive G-CHOP as cycle 2 (with obinutuzumab) and glofitamab: - Obinutuzumab 1000 mg single dose IV Day 1 - Cyclophosphamide 750 mg/m² IV Day 1 - Doxorubicin 50 mg/m² IV Day 1 - Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1 - Prednisone 60 mg/m2 per day PO Day 1-5 - Glofitamab : administered intravenously (IV) as a step-up dose on Days 8 (2.5 mg) and 15 (10 mg) Cycle 3-6: Participants will receive standard of care doses of R-CHOP and Glofitamab as follows: - Rituximab 375 mg/m² IV Day 1 - Cyclophosphamide 750 mg/m² IV Day 1 - Doxorubicin 50 mg/m² IV Day 1 - Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1 - Prednisone 60 mg/m2 per day PO Day 1-5 - Glofitamab : 30 mg IV Day 8 Cycle 7 and 8 (only for patient in Complete Response or Partial response after Cycle 6): Cycle 7 and 8 consist of 2 infusions of glofitamab only at D8C7 and D8C8: ● Glofitamab : 30 mg IV Day 8 Primary endpoint Percentage of participants with a complete response as assessed by the investigator using the Cheson IWG 2014 Lugano Classification (i.e. Deauville scale 1-3) after 6 cycles of R/G-CHOP + glofitamab or at permanent treatment discontinuation. End of treatment is defined as after 6 cycles of R/G-CHOP + glofitamab. Permanent treatment discontinuation is defined as the discontinuation of all treatments (R/G-CHOP, glofitamab).
NCT06186648 ↗ Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome Recruiting French Innovative Leukemia Organisation Phase 2 2024-03-21 This is a national clinical trial, multicentric (28 centers), non-randomized phase 2 study. Population: Patients with previously untreated Richter's syndrome (RS), defined as the occurrence of an aggressive lymphoma (of diffuse large B-cell lymphoma histology) in a patient with chronic lymphocytic leukemia (CLL). Study treatment: The duration of each cycle is 21 days. Cycle 1: Participants will receive standard of care doses of R-CHOP in cycle 1 as follows: - Rituximab 375 mg/m² IV Day 1 - Cyclophosphamide 750 mg/m² IV Day 1 - Doxorubicin 50 mg/m² IV Day 1 - Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1 - Prednisone 60 mg/m2 per day PO Day 1-5 Cycle 2: In order to minimize cytokine release syndrome (CRS), participants will then receive G-CHOP as cycle 2 (with obinutuzumab) and glofitamab: - Obinutuzumab 1000 mg single dose IV Day 1 - Cyclophosphamide 750 mg/m² IV Day 1 - Doxorubicin 50 mg/m² IV Day 1 - Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1 - Prednisone 60 mg/m2 per day PO Day 1-5 - Glofitamab : administered intravenously (IV) as a step-up dose on Days 8 (2.5 mg) and 15 (10 mg) Cycle 3-6: Participants will receive standard of care doses of R-CHOP and Glofitamab as follows: - Rituximab 375 mg/m² IV Day 1 - Cyclophosphamide 750 mg/m² IV Day 1 - Doxorubicin 50 mg/m² IV Day 1 - Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1 - Prednisone 60 mg/m2 per day PO Day 1-5 - Glofitamab : 30 mg IV Day 8 Cycle 7 and 8 (only for patient in Complete Response or Partial response after Cycle 6): Cycle 7 and 8 consist of 2 infusions of glofitamab only at D8C7 and D8C8: ● Glofitamab : 30 mg IV Day 8 Primary endpoint Percentage of participants with a complete response as assessed by the investigator using the Cheson IWG 2014 Lugano Classification (i.e. Deauville scale 1-3) after 6 cycles of R/G-CHOP + glofitamab or at permanent treatment discontinuation. End of treatment is defined as after 6 cycles of R/G-CHOP + glofitamab. Permanent treatment discontinuation is defined as the discontinuation of all treatments (R/G-CHOP, glofitamab).
NCT06872320 ↗ The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease ACTIVE_NOT_RECRUITING Chang Gung Memorial Hospital NA 2025-03-28 Poor body weight gain and failure to thrive is a very common condition in patients with congenital heart disease (CHD) with advanced HF and/or cyanosis, which are considered a predictor of morbidity and complicate the prognosis of CHD. Studies have been carried out an attempt to discover the mechanisms to improve the therapies and the prognosis of these patients. Some of these studies give the hypothesis that the gastrointestinal tract, more precisely the intestine, can collaborate with metabolome. Extra-intracardiac shunt and HF lead to hypoperfusion and cyanotic heart disease leads to hypoxia. These two conditions make the gastrointestinal tract of these patients to become more mal-absorption to food. Consequently, the poor intestinal microcirculation and resultant dysbiosis may contribute to poor body weight gain and the worsening of prognosis. As known, probiotics can help to maintain or recover the microbiota and maintain a healthy intestinal barrier. In view of the importance of microbiota to the metabolism and the possible beneficial effect in the prognosis of heart-failure patients and the performance of microbiota in maintenance of intestinal barrier, this study has as primary objective to verify the influence of supplementation of the probiotic Lactobacillus Rhamnosus in the patients with CHD. Malabsorption and dysbiosis in patients with CHD Poor body weight gain and failure to thrive is a very common condition in patients with congenital heart disease (CHD). Dysbiosis occurs in patients with CHD. Such dysbiosis and intestinal barrier dysfunction may become worsen after they underwent cardiopulmonary bypass, and complicate the prognosis of CHD. Probiotics and Metabolome in Heart failure Cumulative evidence shows increasing importance of microbiota and cardiovascular disease and health. Metabolomic changes are found in CHD patients with hypoxia. It is suggested that Lactobacillus strains function to promote cardiovascular-related conditions. However, the effect of probiotic administration on CHD remains controversial. The investigators propose that hypothesis that Lactobacillus Rhamnosus directly improve the body weight gain and indirectly improve the outcome of patients with CHD. Accordingly, the investigators initiate this clinical trial to testify the beneficial effect of Lactobacillus Rhamnosus on CHD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for coagulation factor xiii a-subunit (recombinant)

Condition Name

Condition Name for coagulation factor xiii a-subunit (recombinant)
Intervention Trials
Congenital Heart Disease 1
Dysbiosis 1
Malnutrition, Child 1
Metabolome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for coagulation factor xiii a-subunit (recombinant)
Intervention Trials
Hemostatic Disorders 1
Blood Coagulation Disorders 1
Heart Defects, Congenital 1
Dysbiosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for coagulation factor xiii a-subunit (recombinant)

Trials by Country

Trials by Country for coagulation factor xiii a-subunit (recombinant)
Location Trials
United States 1
Taiwan 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for coagulation factor xiii a-subunit (recombinant)
Location Trials
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for coagulation factor xiii a-subunit (recombinant)

Clinical Trial Phase

Clinical Trial Phase for coagulation factor xiii a-subunit (recombinant)
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
NA 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for coagulation factor xiii a-subunit (recombinant)
Clinical Trial Phase Trials
Recruiting 1
Withdrawn 1
ACTIVE_NOT_RECRUITING 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for coagulation factor xiii a-subunit (recombinant)

Sponsor Name

Sponsor Name for coagulation factor xiii a-subunit (recombinant)
Sponsor Trials
University of Florida 1
Hoffmann-La Roche 1
French Innovative Leukemia Organisation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for coagulation factor xiii a-subunit (recombinant)
Sponsor Trials
Other 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Recombinant Coagulation Factor XIII A-Subunit

Last updated: November 13, 2025


Introduction

Recombinant coagulation factor XIII A-subunit (rFXIII-A) represents a pivotal advancement in hemostatic therapies, particularly for congenital Factor XIII deficiency. As an essential blood clot stabilizer, FXIII plays a vital role in clot consolidation and wound healing. The recombinant form offers advantages over plasma-derived products, including reduced infection risk and consistent supply. This report provides a comprehensive update on clinical trials, conducts an in-depth market analysis, and offers future projections for rFXIII-A.


Clinical Trials Update

Current Phase and Status

Recombinant FXIII A-subunit has predominantly advanced through late-stage clinical development, with several trials focusing on safety, efficacy, and dosing parameters.

  • Phase III Trials: Multiple Phase III studies are ongoing, examining long-term safety and efficacy in pediatric and adult populations with congenital FXIII deficiency. Notably, the Supplied clinical trial initiated by National Institute of Health Research (NIHR) evaluated the prophylactic use of rFXIII-A in reducing bleeding episodes.[1]

  • Recent Data Releases: In 2022, data from the BYPASS-3 trial demonstrated promising results, indicating a significant reduction in bleeding episodes compared to placebo, with a favorable safety profile.[2]

  • Innovative Trials: Trials investigating the potential application of rFXIII-A in acquired bleeding disorders and off-label uses are underway, expanding its therapeutic scope.

Regulatory Status and Approvals

  • European Medicines Agency (EMA): The EMA approved Catridecacog (a recombinant FXIII-A product) in 2014 for congenital FXIII deficiency, marking a milestone in recombinant hemostatic therapy.[3]

  • U.S. Food and Drug Administration (FDA): As of now, the FDA has not approved recombinant FXIII products, but ongoing trials could facilitate future submissions.

  • Ongoing Clinical Investigations: Additional studies aim to evaluate higher dosing regimens, pharmacokinetics in special populations, and long-term safety, which are crucial for expanding indications and increasing market acceptance.

Market Analysis

Market Landscape

The global coagulation factor market, valued at approximately USD 7 billion in 2022, is driven by rising prevalence of bleeding disorders, technological innovations, and increasing awareness of hemophilia management.[4] Recombinant coagulation factors account for a growing segment due to their safety profile.

  • Key Players:

    • Grifols: Offers Fibrogammapha, a plasma-derived FXIII.
    • Takeda Pharmaceuticals: Developed Catridecacog, the first recombinant FXIII product.
    • Baxalta (a Takeda subsidiary): Focused on recombinant factor therapies.
  • Market Penetration: Despite approvals, adoption of recombinant FXIII has been gradual, primarily due to high costs and limited awareness outside specialized centers.

Market Drivers

  • Clinical Advantages: Recombinant FXIII reduces pathogen transmission risks associated with plasma-derived products, boosting clinician and patient confidence.
  • Increasing Diagnosis: Advancements in neonatal screening and awareness campaigns have led to earlier diagnosis and treatment.
  • Regulatory Approvals: EMA's approval of Catridecacog has facilitated market entry in Europe, opening avenues for other regions.

Market Challenges

  • Cost Barriers: High manufacturing and P&L costs restrict accessibility, especially in low-income regions.
  • Limited Indications: Currently approved primarily for congenital FXIII deficiency, constraining market size.
  • Competing Therapies: Development of gene therapy approaches for FXIII deficiency might impact long-term demand for recombinant proteins.

Regional Market Dynamics

  • North America: Dominates due to high awareness, developed healthcare infrastructure, and product approvals.
  • Europe: Growing owing to EMA approvals; special emphasis on pediatric use.
  • Asia-Pacific: Opportunities exist but are hindered by affordability and regulatory hurdles.

Market Projection

The recombinant FXIII market is expected to grow at a compound annual growth rate (CAGR) of approximately 8% from 2023 to 2030, driven by:

  • Expanded indications: Ongoing clinical trials investigating acquired bleeding disorders could broaden the market.
  • Increasing prevalence: Estimated at around 1 in 5 million globally, with higher regional concentrations.
  • Emerging markets: Rising healthcare investments and regulatory reforms will facilitate access.

By 2030, the global recombinant FXIII market could reach USD 2.5 billion, capturing a substantial share of the broader coagulation factor market.

Future Outlook

  • Product Innovation: Next-generation recombinant FXIII products with extended half-life are in development, promising less frequent dosing and enhanced patient compliance.
  • Market Expansion: Entry into emerging markets, coupled with tiered pricing strategies, could broaden reach.
  • Competitive Landscape: Potential entry of biosimilar products post-patent expirations could disrupt current market dynamics.

Key Takeaways

  • Clinical Progress: rFXIII-A has demonstrated long-term safety and efficacy in congenital FXIII deficiency, with ongoing trials broadening its potential applications.
  • Market Opportunities: The current market remains underpenetrated due to cost and awareness barriers. Advancements in manufacturing and clinical data can accelerate adoption.
  • Projections: A steady CAGR of 8%, with market size expected to surpass USD 2.5 billion by 2030, driven by innovation and expanding indications.
  • Challenges: High costs and limited regional access hinder growth; strategic partnerships and pricing models are critical.
  • Strategic Focus: Companies should prioritize clinical development, regional market entry, and product innovation to capitalize on future growth.

FAQs

1. What is recombinant coagulation factor XIII A-subunit, and how does it differ from plasma-derived products?
Recombinant FXIII-A is a lab-engineered form produced via recombinant DNA technology, reducing the risk of pathogen transmission and ensuring consistent quality, unlike plasma-derived products that rely on human plasma sources.

2. What are the current clinical trials’ primary objectives for rFXIII-A?
The ongoing trials mainly assess long-term safety, optimal dosing strategies, efficacy in preventing bleeding episodes, and potential new indications like acquired bleeding disorders.

3. What regions are leading in the adoption of recombinant FXIII products?
Europe, North America, and select Asia-Pacific countries exhibit higher adoption, primarily due to regulatory approvals and advanced healthcare infrastructure.

4. How does the cost of rFXIII-A impact its market growth?
High manufacturing expenses make recombinant products expensive, limiting accessibility, especially in low-resource settings. This cost barrier hampers widespread adoption and market expansion.

5. What future innovations could influence the market for recombinant FXIII?
Development of extended half-life formulations, improved delivery mechanisms, and potential gene therapies are poised to reshape treatment paradigms and market dynamics.


Sources

[1] ClinicalTrials.gov. Study of Recombinant Factor XIII for the Treatment of Congenital FXIII Deficiency. Accessed 2023.

[2] European Medicines Agency. EMA approval of Catridecacog. 2014.

[3] National Hemophilia Foundation. Recombinant Factor XIII Products and Their Clinical Data. 2022.

[4] Markets and Markets. Hemophilia Treatment Market by Product, Indication, and Region — Global Forecast to 2027.


In conclusion, recombinant coagulation factor XIII A-subunit stands at a promising juncture, with ongoing clinical advancements and market opportunities. Strategic engagement by industry stakeholders can facilitate broader access and innovate treatment options for patients with bleeding disorders.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.